title: Chylomicronemia elicits atherosclerosis in mice--brief report.
abstract: OBJECTIVE
  The risk of atherosclerosis in the setting of chylomicronemia has been a topic of debate. In this study, we examined susceptibility to atherosclerosis in Gpihbp1-deficient mice (Gpihbp1(-/-)), which manifest severe chylomicronemia as a result of defective lipolysis.
  
  
  RESULTS
  Gpihbp1(-/-) mice on a chow diet have plasma triglyceride and cholesterol levels of 2812+/-209 and 319+/-27 mg/dL, respectively. Even though nearly all of the lipids were contained in large lipoproteins (50 to 135 nm), the mice developed progressive aortic atherosclerosis. In other experiments, we found that both Gpihbp1-deficient "apo-B48-only" mice and Gpihbp1-deficient "apo-B100-only" mice manifest severe chylomicronemia. Thus, GPIHBP1 is required for the processing of both apo-B48- and apo-B100-containing lipoproteins.
  
  
  CONCLUSIONS
  Chylomicronemia causes atherosclerosis in mice. Also, we found that GPIHBP1 is required for the lipolytic processing of both apo-B48- and apo-B100-containing lipoproteins.
authors.affiliation: Departments of Medicine, University of California, Los Angeles, USA.
authors.forename: Michael M
authors.initials: MM
authors.lastname: Weinstein
authors.forename: Liya
authors.initials: L
authors.lastname: Yin
authors.forename: Yiping
authors.initials: Y
authors.lastname: Tu
authors.forename: Xuping
authors.initials: X
authors.lastname: Wang
authors.forename: Xiaohui
authors.initials: X
authors.lastname: Wu
authors.forename: Lawrence W
authors.initials: LW
authors.lastname: Castellani
authors.forename: Rosemary L
authors.initials: RL
authors.lastname: Walzem
authors.forename: Aldons J
authors.initials: AJ
authors.lastname: Lusis
authors.forename: Loren G
authors.initials: LG
authors.lastname: Fong
authors.forename: Anne P
authors.initials: AP
authors.lastname: Beigneux
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Young
mesh_terms: D000821:Animal Feed; D000818:Animals; D001018:Aortic Diseases / Q000453:epidemiology / Q000235:genetics / Q000378:metabolism; D053299:Apolipoprotein B-100 / Q000378:metabolism*; D053283:Apolipoprotein B-48 / Q000378:metabolism*; D050197:Atherosclerosis / Q000453:epidemiology / Q000235:genetics / Q000378:metabolism*; D002914:Chylomicrons / Q000378:metabolism*; D005227:Fatty Acids / Q000378:metabolism; D005260:Female; D020022:Genetic Predisposition to Disease; D008066:Lipolysis / Q000502:physiology; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D018110:Receptors, Lipoprotein / Q000235:genetics / Q000378:metabolism*; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D002914:Chylomicrons; D005227:Fatty Acids; C472779:GPI-HBP1 protein, mouse; D018110:Receptors, Lipoprotein; D014280:Triglycerides